Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL SOFT TISSUE ALLOGRAFT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL SOFT TISSUE ALLOGRAFT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES VOLUME DATA
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL SOFT TISSUE ALLOGRAFT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER'S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYSIS AND RECOMMENDATIONS
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNOLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 REIMBURSEMENT FRAMEWORK
13 OPPUTUNITY MAP ANALYSIS
14 INSTALLED BASE DATA
15 VALUE CHAIN ANALYSIS
16 HEALTHCARE ECONOMY
16.1 HEALTHCARE EXPENDITURE
16.2 CAPITAL EXPENDITURE
16.3 CAPEX TRENDS
16.4 CAPEX ALLOCATION
16.5 FUNDING SOURCES
16.6 INDUSTRY BENCHMARKS
16.7 GDP RATION IN OVERALL GDP
16.8 HEALTHCARE SYSTEM STRUCTURE
16.9 GOVERNMENT POLICIES
16.1 ECONOMIC DEVELOPMENT
17 GLOBAL SOFT TISSUE ALLOGRAFT MARKET, BY TYPE
17.1 OVERVIEW
17.2 CARTILAGE ALLOGRAFT
17.2.1 BY PRODUCT
17.2.1.1. COSTAL CARTILAGE
17.2.1.2. OSTEOCHONDRAL ALLOGRAFT PLUGS
17.2.1.3. OSTEOCHONDRAL ALLOGRAFT
17.2.1.4. OTHERS
17.2.2 BY CARTILAGE TYPE
17.2.2.1. HYALINE CARTILAGE
17.2.2.2. ELASTIC CARTILAGE
17.2.2.3. FIBRO CARTILAGE
17.2.3 OTHERS
17.3 TENDON ALLOGRAFT
17.3.1 BY PRODUCT
17.3.1.1. NON-BONE TENDON ALLOGRAFT
17.3.1.2. BONE & BTB TENDON ALLOGRAFT
17.3.2 BY TENDON TYPE
17.3.2.1. TIBIALIS
17.3.2.1.1. ANTERIOR TIBIALIS
17.3.2.1.2. POSTERIOR TIBIALIS
17.3.2.2. ARCHILLES TENDON
17.3.2.2.1. ACHILLES TENDON
17.3.2.2.2. ACHILLES TENDON WITH BONE BLOCK
17.3.2.2.3. PRE-SHAPED ACHILLES
17.3.2.2.4. OTHERS
17.3.2.3. PATELLAR TENDON
17.3.2.4. HAMSTRING
17.3.3 OTHERS
17.4 AMNIOTIC ALLOGRAFT
17.4.1 BY LENGTH
17.4.1.1. 14 MM DISC
17.4.1.2. 16 MM DISC
17.4.1.3. OTHERS
17.4.2 BY DIMENSION
17.4.2.1. 2 CM × 4 CM SHEET
17.4.2.2. 3 CM × 3 CM SHEET
17.4.2.3. 4 CM × 4 CM SHEET
17.4.2.4. OTHERS
17.4.3 OTHERS
17.5 MENISCUS ALLOGRAFT
17.5.1 MEDIAL ALLOGRAFT
17.5.2 LATERAL ALLOGRAFT
17.6 DENTAL ALLOGRAFT
17.6.1 FREE GINGIVAL GRAFT
17.6.2 CONNECTIVE TISSUE GRAFT
17.6.3 PEDICLE GRAFT
17.7 COLLAGEN ALLOGRAFT
17.8 OTHERS
18 GLOBAL SOFT TISSUE ALLOGRAFT MARKET, BY SOURCE
18.1 OVERVIEW
18.2 HUMAN ALLOGRAFTS
18.2.1 LIVING DONOR
18.2.2 DECEASED DONOR
18.3 SYNTHETIC ALLOGRAFT
19 GLOBAL SOFT TISSUE ALLOGRAFT MARKET, BY PROCESSING METHOD
19.1 OVERVIEW
19.2 FRESH FROZEN
19.3 DEHYDRATED
19.4 STERILIZED
19.4.1 GAMMA IRRADIATION
19.4.2 ELECTRON-BEAM IRRADIATION
19.4.3 ETHYLENE OXIDE STERILIZATION
19.4.4 PERACETIC ACID–ETHANOL
19.5 OTHERS
20 GLOBAL SOFT TISSUE ALLOGRAFT MARKET, BY POPULATION TYPE
20.1 OVERVIEW
20.2 PEDIATRIC
20.2.1 MALE
20.2.2 FEMALE
20.3 ADULT
20.3.1 MALE
20.3.2 FEMALE
20.4 GERIARTIC
20.4.1 MALE
20.4.2 FEMALE
21 GLOBAL SOFT TISSUE ALLOGRAFT MARKET, BY APPLICATION
21.1 OVERVIEW
21.2 SPINAL
21.3 ORTHOPEDIC
21.3.1 SPORTS MEDICINE
21.3.2 SPINE SURGERIES
21.3.3 GENERAL ORTHOPEDIC
21.3.4 RECONSTRUCTION
21.3.5 OTHERS
21.4 DENTISTRY
21.4.1 DENTAL SENSITIVITY
21.4.2 DENTAL AESTHETICS
21.4.3 OTHERS
21.5 WOUND CARE
21.6 PLASTIC SURGERY
21.7 MUSCULOSKELETAL REPAIR AND RECONSTRUCTION
21.8 OTHER APPLICATIONS
22 GLOBAL SOFT TISSUE ALLOGRAFT MARKET, BY END USER
22.1 OVERVIEW
22.2 HOSPITALS
22.2.1 BY TYPE
22.2.1.1. PUBLIC
22.2.1.2. PRIVATE
22.2.2 BY TIER
22.2.2.1. TIER 1
22.2.2.2. TIER 2
22.2.2.3. TIER 3
22.3 SPECIALTY CLINICS
22.3.1 ORTHOPEDIC CLINICS
22.3.2 DENTAL CLINICS
22.3.3 OTHERS
22.4 TRAUMA CENTERS
22.5 AESTHETICS CENTERS
22.6 AMBULATORY SURGICAL CENTERS
22.7 ACADEMIC AND RESEARCH INSTITUTES
22.8 OTHER
23 GLOBAL SOFT TISSUE ALLOGRAFT MARKET, BY DISTRIBUTION CHANNEL
23.1 OVERVIEW
23.2 DIRECT TENDER
23.3 RETAIL SALES
23.3.1 ONLINE SALES
23.3.2 OFFLINE SALES
23.4 OTHERS
24 GLOBAL SOFT TISSUE ALLOGRAFT MARKET, COMPANY LANDSCAPE
24.1 COMPANY SHARE ANALYSIS: GLOBAL
24.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
24.3 COMPANY SHARE ANALYSIS: EUROPE
24.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
24.5 MERGERS & ACQUISITIONS
24.6 NEW PRODUCT DEVELOPMENT & APPROVALS
24.7 EXPANSIONS
24.8 REGULATORY CHANGES
24.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
25 GLOBAL SOFT TISSUE ALLOGRAFT MARKET, SWOT AND DBMR ANALYSIS
26 GLOBAL SOFT TISSUE ALLOGRAFT MARKET, BY GEOGRAPHY
26.1 GLOBAL SOFT TISSUE ALLOGRAFT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
26.1.1 NORTH AMERICA
26.1.1.1. U.S.
26.1.1.2. CANADA
26.1.1.3. MEXICO
26.1.2 EUROPE
26.1.2.1. GERMANY
26.1.2.2. FRANCE
26.1.2.3. U.K.
26.1.2.4. HUNGARY
26.1.2.5. LITHUANIA
26.1.2.6. AUSTRIA
26.1.2.7. IRELAND
26.1.2.8. NORWAY
26.1.2.9. POLAND
26.1.2.10. ITALY
26.1.2.11. SPAIN
26.1.2.12. RUSSIA
26.1.2.13. TURKEY
26.1.2.14. NETHERLANDS
26.1.2.15. SWITZERLAND
26.1.2.16. REST OF EUROPE
26.1.3 ASIA-PACIFIC
26.1.3.1. JAPAN
26.1.3.2. CHINA
26.1.3.3. SOUTH KOREA
26.1.3.4. INDIA
26.1.3.5. AUSTRALIA
26.1.3.6. SINGAPORE
26.1.3.7. THAILAND
26.1.3.8. MALAYSIA
26.1.3.9. INDONESIA
26.1.3.10. PHILIPPINES
26.1.3.11. VIETNAM
26.1.3.12. REST OF ASIA-PACIFIC
26.1.4 SOUTH AMERICA
26.1.4.1. BRAZIL
26.1.4.2. ARGENTINA
26.1.4.3. PERU
26.1.4.4. COLOMBIA
26.1.4.5. VENEZUELA
26.1.4.6. REST OF SOUTH AMERICA
26.1.5 MIDDLE EAST AND AFRICA
26.1.5.1. SOUTH AFRICA
26.1.5.2. SAUDI ARABIA
26.1.5.3. UAE
26.1.5.4. EGYPT
26.1.5.5. KUWAIT
26.1.5.6. ISRAEL
26.1.5.7. REST OF MIDDLE EAST AND AFRICA
26.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
27 GLOBAL SOFT TISSUE ALLOGRAFT MARKET, COMPANY PROFILE
27.1 ARTHREX, INC.
27.1.1 COMPANY OVERVIEW
27.1.2 REVENUE ANALYSIS
27.1.3 GEOGRAPHIC PRESENCE
27.1.4 PRODUCT PORTFOLIO
27.1.5 RECENT DEVELOPMENTS
27.2 ZIMMER BIOMET
27.2.1 COMPANY OVERVIEW
27.2.2 REVENUE ANALYSIS
27.2.3 GEOGRAPHIC PRESENCE
27.2.4 PRODUCT PORTFOLIO
27.2.5 RECENT DEVELOPMENTS
27.3 OSTEOGENICS BIOMEDICAL
27.3.1 COMPANY OVERVIEW
27.3.2 REVENUE ANALYSIS
27.3.3 GEOGRAPHIC PRESENCE
27.3.4 PRODUCT PORTFOLIO
27.3.5 RECENT DEVELOPMENTS
27.4 CONMED CORPORATION
27.4.1 COMPANY OVERVIEW
27.4.2 REVENUE ANALYSIS
27.4.3 GEOGRAPHIC PRESENCE
27.4.4 PRODUCT PORTFOLIO
27.4.5 RECENT DEVELOPMENTS
27.5 XTANT MEDICAL
27.5.1 COMPANY OVERVIEW
27.5.2 REVENUE ANALYSIS
27.5.3 GEOGRAPHIC PRESENCE
27.5.4 PRODUCT PORTFOLIO
27.5.5 RECENT DEVELOPMENTS
27.6 INTEGRA LIFESCIENCES CORPORATION
27.6.1 COMPANY OVERVIEW
27.6.2 REVENUE ANALYSIS
27.6.3 GEOGRAPHIC PRESENCE
27.6.4 PRODUCT PORTFOLIO
27.6.5 RECENT DEVELOPMENTS
27.7 STRYKER
27.7.1 COMPANY OVERVIEW
27.7.2 REVENUE ANALYSIS
27.7.3 GEOGRAPHIC PRESENCE
27.7.4 PRODUCT PORTFOLIO
27.7.5 RECENT DEVELOPMENTS
27.8 RTI SURGICAL
27.8.1 COMPANY OVERVIEW
27.8.2 REVENUE ANALYSIS
27.8.3 GEOGRAPHIC PRESENCE
27.8.4 PRODUCT PORTFOLIO
27.8.5 RECENT DEVELOPMENTS
27.9 INSTITUT STRAUMANN AG
27.9.1 COMPANY OVERVIEW
27.9.2 REVENUE ANALYSIS
27.9.3 GEOGRAPHIC PRESENCE
27.9.4 PRODUCT PORTFOLIO
27.9.5 RECENT DEVELOPMENTS
27.1 DEPUY SYNTHES
27.10.1 COMPANY OVERVIEW
27.10.2 REVENUE ANALYSIS
27.10.3 GEOGRAPHIC PRESENCE
27.10.4 PRODUCT PORTFOLIO
27.10.5 RECENT DEVELOPMENTS
27.11 ORIGIN BIOLOGICS
27.11.1 COMPANY OVERVIEW
27.11.2 REVENUE ANALYSIS
27.11.3 GEOGRAPHIC PRESENCE
27.11.4 PRODUCT PORTFOLIO
27.11.5 RECENT DEVELOPMENTS
27.12 MTF BIOLOGICS
27.12.1 COMPANY OVERVIEW
27.12.2 REVENUE ANALYSIS
27.12.3 GEOGRAPHIC PRESENCE
27.12.4 PRODUCT PORTFOLIO
27.12.5 RECENT DEVELOPMENTS
27.13 BONE BANK ALLOGRAFTS
27.13.1 COMPANY OVERVIEW
27.13.2 REVENUE ANALYSIS
27.13.3 GEOGRAPHIC PRESENCE
27.13.4 PRODUCT PORTFOLIO
27.13.5 RECENT DEVELOPMENTS
27.14 ALAMO BIOLOGICS
27.14.1 COMPANY OVERVIEW
27.14.2 REVENUE ANALYSIS
27.14.3 GEOGRAPHIC PRESENCE
27.14.4 PRODUCT PORTFOLIO
27.14.5 RECENT DEVELOPMENTS
27.15 AEDICELL
27.15.1 COMPANY OVERVIEW
27.15.2 REVENUE ANALYSIS
27.15.3 GEOGRAPHIC PRESENCE
27.15.4 PRODUCT PORTFOLIO
27.15.5 RECENT DEVELOPMENTS
27.16 VIVEX BIOLOGICS, INC.
27.16.1 COMPANY OVERVIEW
27.16.2 REVENUE ANALYSIS
27.16.3 GEOGRAPHIC PRESENCE
27.16.4 PRODUCT PORTFOLIO
27.16.5 RECENT DEVELOPMENTS
27.17 VENTERIS MEDICAL LLC
27.17.1 COMPANY OVERVIEW
27.17.2 REVENUE ANALYSIS
27.17.3 GEOGRAPHIC PRESENCE
27.17.4 PRODUCT PORTFOLIO
27.17.5 RECENT DEVELOPMENTS
27.18 ALLIQUA BIOMEDICAL, INC.
27.18.1 COMPANY OVERVIEW
27.18.2 REVENUE ANALYSIS
27.18.3 GEOGRAPHIC PRESENCE
27.18.4 PRODUCT PORTFOLIO
27.18.5 RECENT DEVELOPMENTS
27.19 TIDES MEDICAL
27.19.1 COMPANY OVERVIEW
27.19.2 REVENUE ANALYSIS
27.19.3 GEOGRAPHIC PRESENCE
27.19.4 PRODUCT PORTFOLIO
27.19.5 RECENT DEVELOPMENTS
27.2 ELUTIA
27.20.1 COMPANY OVERVIEW
27.20.2 REVENUE ANALYSIS
27.20.3 GEOGRAPHIC PRESENCE
27.20.4 PRODUCT PORTFOLIO
27.20.5 RECENT DEVELOPMENTS
27.21 PROMETHEAN
27.21.1 COMPANY OVERVIEW
27.21.2 REVENUE ANALYSIS
27.21.3 GEOGRAPHIC PRESENCE
27.21.4 PRODUCT PORTFOLIO
27.21.5 RECENT DEVELOPMENTS
27.22 TISSUE REGENIX
27.22.1 COMPANY OVERVIEW
27.22.2 REVENUE ANALYSIS
27.22.3 GEOGRAPHIC PRESENCE
27.22.4 PRODUCT PORTFOLIO
27.22.5 RECENT DEVELOPMENTS
27.23 PARAMETRICS MEDICAL.
27.23.1 COMPANY OVERVIEW
27.23.2 REVENUE ANALYSIS
27.23.3 GEOGRAPHIC PRESENCE
27.23.4 PRODUCT PORTFOLIO
27.23.5 RECENT DEVELOPMENTS
27.24 ORGANOGENESIS INC.
27.24.1 COMPANY OVERVIEW
27.24.2 REVENUE ANALYSIS
27.24.3 GEOGRAPHIC PRESENCE
27.24.4 PRODUCT PORTFOLIO
27.24.5 RECENT DEVELOPMENTS
27.25 AMNIO TECHNOLOGY, LLC
27.25.1 COMPANY OVERVIEW
27.25.2 REVENUE ANALYSIS
27.25.3 GEOGRAPHIC PRESENCE
27.25.4 PRODUCT PORTFOLIO
27.25.5 RECENT DEVELOPMENTS
27.26 STIMLABS LLC
27.26.1 COMPANY OVERVIEW
27.26.2 REVENUE ANALYSIS
27.26.3 GEOGRAPHIC PRESENCE
27.26.4 PRODUCT PORTFOLIO
27.26.5 RECENT DEVELOPMENTS
27.27 SKYE BIOLOGICS HOLDINGS, LLC
27.27.1 COMPANY OVERVIEW
27.27.2 REVENUE ANALYSIS
27.27.3 GEOGRAPHIC PRESENCE
27.27.4 PRODUCT PORTFOLIO
27.27.5 RECENT DEVELOPMENTS
27.28 APPLIED BIOLOGICS
27.28.1 COMPANY OVERVIEW
27.28.2 REVENUE ANALYSIS
27.28.3 GEOGRAPHIC PRESENCE
27.28.4 PRODUCT PORTFOLIO
27.28.5 RECENT DEVELOPMENTS
28 RELATED REPORTS
29 CONCLUSION
30 QUESTIONNAIRE
31 ABOUT DATA BRIDGE MARKET RESEARCH
